SUZHOU, CHINA, Aug 30, 2021 - (ACN Newswire via SEAPRWire.com) - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.Dr.Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, "In the first half of 2021, Kintor Pharma has made great progress in areas including research, clinical operations, and business cooperation with reputable partners. More specifically, proxalutamide, an innovative androgen receptor antagonist for the treatment of COVID-19 infection, is in three phase III multi-regional clinical trials (MRCT) approved by regulators in the United States, Brazil, and other countries. Recently, in a major milestone, proxalutamide was granted its first emergency use authorization (EUA) by the Paraguay. Looking further out, our company is accelerating the global clinical development of existing products pipeline and remains focus...